Clinical significance of integrin β6 as a tumor recurrence factor in follicular thyroid carcinoma
- PMID: 24844802
- DOI: 10.1002/hed.23780
Clinical significance of integrin β6 as a tumor recurrence factor in follicular thyroid carcinoma
Abstract
Background: Overexpression of integrin β6 plays an important role in a variety of malignant tumor invasion and metastasis.
Methods: The expression levels of integrin β6, matrix metalloproteinase (MMP)-2 and MMP-9 were analyzed by immunohistochemistry with human follicular thyroid carcinomas. Then we investigated their correlation with clinical outcomes parameters, relationship, and the survival time.
Results: The integrin β6 staining was expressed in cellular membrane and cytoplasm of follicular thyroid carcinoma cells. The MMP-2 and MMP-9 expressions were mainly found in cellular cytoplasm. In correlation with the clinical outcome parameters of 60 patients, there were significant statistical differences of integrin β6, MMP-2, and MMP-9 expression levels in different size of tumor. Integrin β6 and MMP-9 expressions have significant statistical differences in T classifications. MMP-2 and MMP-9 expressions have significant statistical differences in different M classification. Other clinical outcome parameters had no significant statistical differences.
Conclusion: Integrin β6 expression correlated significantly with MMP-9 expression, and may be a valuable recurrence indicator for follicular thyroid carcinomas.
Keywords: MMP-9; follicular thyroid carcinoma; integrin β6; matrix metalloproteinase (MMP)-2; recurrence.
© 2014 Wiley Periodicals, Inc.
Similar articles
-
Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies.Int J Cancer. 2009 Aug 15;125(4):894-901. doi: 10.1002/ijc.24462. Int J Cancer. 2009. PMID: 19480010
-
[Pathologic study of expression and significance of matrix metalloproteinases-9, tissue inhibitor of metalloproteinase-1, vascular endothelial growth factor and transforming growth factor beta-1 in papillary carcinoma and follicular carcinoma of thyroid].Zhonghua Bing Li Xue Za Zhi. 2009 Dec;38(12):824-8. Zhonghua Bing Li Xue Za Zhi. 2009. PMID: 20193458 Chinese.
-
Binding of MMP-9-degraded fibronectin to β6 integrin promotes invasion via the FAK-Src-related Erk1/2 and PI3K/Akt/Smad-1/5/8 pathways in breast cancer.Oncol Rep. 2015 Sep;34(3):1345-52. doi: 10.3892/or.2015.4103. Epub 2015 Jul 2. Oncol Rep. 2015. PMID: 26134759
-
Clinicopathologic evaluation of immunohistochemical CD147 and MMP-2 expression in differentiated thyroid carcinoma.Jpn J Clin Oncol. 2008 Aug;38(8):528-33. doi: 10.1093/jjco/hyn065. Epub 2008 Jul 29. Jpn J Clin Oncol. 2008. PMID: 18664479
-
Thyroid-like follicular carcinoma of the kidney: one case report and review of the literature.Am J Clin Pathol. 2015 Nov;144(5):796-804. doi: 10.1309/AJCP6P0STAAHOTTG. Am J Clin Pathol. 2015. PMID: 26486745 Review.
Cited by
-
Synergistic cytotoxicity of the dipeptidyl peptidase-IV inhibitor gemigliptin with metformin in thyroid carcinoma cells.Endocrine. 2018 Feb;59(2):383-394. doi: 10.1007/s12020-017-1503-2. Epub 2017 Dec 28. Endocrine. 2018. PMID: 29285650
-
Higher Integrin Alpha 3 Beta1 Expression in Papillary Thyroid Cancer Is Associated with Worst Outcome.Cancers (Basel). 2021 Jun 11;13(12):2937. doi: 10.3390/cancers13122937. Cancers (Basel). 2021. PMID: 34208249 Free PMC article.
-
The Role of MMP-9 and MMP-9 Inhibition in Different Types of Thyroid Carcinoma.Molecules. 2023 Apr 25;28(9):3705. doi: 10.3390/molecules28093705. Molecules. 2023. PMID: 37175113 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous